Renaissance Capital logo

Bio Blast Pharma Priced, Nasdaq: ORPN

Biotech developing treatments for rare and ultra-rare genetic diseases.

Industry: Health Care

First Day Return: -23.6%

Industry: Health Care

Biotech developing treatments for rare and ultra-rare genetic diseases.
more less

Bio Blast Pharma (ORPN) Performance